Stifel Financial Corp Has $43.58 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Stifel Financial Corp boosted its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 24.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 326,140 shares of the life sciences company's stock after purchasing an additional 64,986 shares during the period. Stifel Financial Corp owned about 0.21% of Illumina worth $43,582,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in ILMN. Versant Capital Management Inc increased its stake in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after purchasing an additional 146 shares in the last quarter. Golden State Wealth Management LLC bought a new position in shares of Illumina in the 4th quarter worth approximately $32,000. Assetmark Inc. boosted its stake in shares of Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after acquiring an additional 296 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Illumina in the fourth quarter worth about $45,000. Finally, Lee Danner & Bass Inc. bought a new position in shares of Illumina during the 4th quarter valued at approximately $48,000. Institutional investors own 89.42% of the company's stock.

Wall Street Analyst Weigh In

ILMN has been the subject of several research reports. Citigroup lowered their target price on Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a report on Monday, April 7th. Piper Sandler upped their price objective on shares of Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Canaccord Genuity Group decreased their target price on Illumina from $115.00 to $92.00 and set a "hold" rating on the stock in a research report on Tuesday. Guggenheim reduced their price objective on shares of Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Finally, TD Cowen downgraded Illumina from a "buy" rating to a "hold" rating and decreased their target price for the company from $177.00 to $140.00 in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $137.55.

Illumina Trading Down 0.2 %

ILMN stock traded down $0.17 during midday trading on Tuesday, reaching $77.05. The company's stock had a trading volume of 400,392 shares, compared to its average volume of 2,274,608. The business's 50-day simple moving average is $81.51 and its 200-day simple moving average is $117.39. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The stock has a market cap of $12.19 billion, a PE ratio of -10.00, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.